Clinicians have a growing number of options for treating immunoglobulin A nephropathy.
Kidney function remained stable throughout the 25 week treatment period.
In many cases, older patients with end-stage kidney disease would be better off with conservative kidney management focused on enhancing quality of life rather than going on dialysis.
Kidney function was not harmed over 52 weeks of pegloticase and methotrexate co-therapy in patients with uncontrolled gout at baseline.
Sparsentan is a dual endothelin and angiotensin receptor antagonist.
The rate of AKI requiring dialysis among patients hospitalized with pneumonia was 2.5% for those with CKD compared with 0.03% for those without CKD.
Medical nutritional therapy may need to be combined with anti-hyperkalemia therapy to prevent recurrence, investigators suggested.
Study findings indicate synergistic effects of SGLT2 inhibitors and MRAs on albuminuria.
Use of intravenous iron and ESAs was low among patients with stage 3 to 5 CKD.
The rate of esophageal and gastric erosions among patients on dialysis eligible for anemia treatment was approximately 49 events per 100 patient-years, investigators report.
Patients receiving peritoneal dialysis rather than hemodialysis or both modalities have the lowest rate of ESA hyporesponse.
Survey findings highlight the need to train staff on comprehensive conservative care.
Patients with persistent ESA hyporesponse had especially high rates of adverse events.
The prevalence of diabetic kidney disease is higher among US veterans than the general population, investigators noted.
Black living kidney donors have a significant 17% higher risk for systolic hypertension compared with their White counterparts.
The new tool goes beyond hemoglobin measurement to include the effects of anemia on patients’ quality of life.
Investigators report no significant improvement in cardiovascular or overall mortality in patients on dialysis.